Status:
COMPLETED
the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome
Lead Sponsor:
Mansoura University Children Hospital
Conditions:
Down Syndrome
Eligibility:
All Genders
6-7 years
Phase:
PHASE2
Brief Summary
Down syndrome is a genetic disorder that causes delay in both physical growth and mental development. It is the most frequently reported chromosomal abnormality and the most common genetic syndrome. ...
Eligibility Criteria
Inclusion
- Infants were confirmed to have Down syndrome of non disjunction genotype.
- Age was around 6 month, at time of recruitment.
- Legal guardians accepted to participate in the study and sign the informed consent.
Exclusion
- Patients having uncontrolled hypothyroidism
- Patients with brain malformations other than the expected in infant with Down syndrome.
- Patients with hearing and / or vision impairments.
- severe congenital heart disease
- Patients having contraindications for the use of Cerebrolysin
Key Trial Info
Start Date :
September 30 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2019
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT04751136
Start Date
September 30 2016
End Date
August 30 2019
Last Update
February 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University Children Hospital
Al Mansurah, Dakahlia Governorate, Egypt, 35516